Laboratory test results showed that, within the human digestive system, the Zantac medication does not form the impurity known as NDMA, according to an FDA official. NDMA has been classified as a probable human carcinogen based on lab tests.
As part of its investigation into an impurity found in heartburn medication Zantac OTC, the US Food and Drug Administration has found levels of the impurity"similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats."
Laboratory test results showed that, within the human digestive system, the Zantac medication does not form the impurity known as N-nitrosodimethylamine or NDMA, said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, in a statement on Friday.Zantac is a type of ranitidine, a medication for heartburn, stomach ulcers and other conditions that cause too much stomach acid.
If you take over-the-counter ranitidine products or nizatidine, antacid medications, the FDA recommends considering other over-the-counter products for their conditions. FDA tests of other medications, like Pepcid, Tagamet, Nexium, Prevacid and Prilosec, have shown no NDMA impurities in the medicines, according to Woodcock's statement. If you take prescription ranitidine or nizatidine, you should talk to your doctor about other treatment option.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA testing indicates Zantac does not form carcinogen in usersThe results come from lab tests, but the agency said that it still plans to test the drug in human patients.
Leer más »
FDA Approves First Artificial TumorWASHINGTON—Following years of research and testing, the U.S. Food and Drug Administration officially approved a groundbreaking artificial tumor Tuesday, marking the first time a synthetic malignant growth has been cleared for use in patients across the country. “There were obviously significant complications in devising a tumor substitute the human body would accept, but we now have an artificial neoplasm that serves the same physiological functions as an organic abnormal growth of tissue,” said Jeffrey Shuren of the FDA’s Center for Devices and Radiological Health, adding that the polymer-based lump can be safely implanted in patients regardless of age, health, or medical history during a minimally invasive and relatively quick two-hour surgical procedure. “This synthetic tumor is remarkably lightweight, malignant, and capable of naturally metastasizing throughout the body. It also has the benefit of being incredibly small—roughly the size of a dime—but once in the body, it will grow two to three times in size and will get to work immediately replicating itself.” Shuren added that while initial prototypes of the device had only enough battery power to last a few days, the approved version is capable of going for several years or more, or until its objective has been completed.
Leer más »
Trump to pick Texas cancer doctor to head FDAPresident Donald Trump on Friday will nominate Stephen Hahn, a well-regarded cancer specialist and hospital administrator, to lead the FDA, three people familiar with the decision told POLITICO. If confirmed by the Senate, the top FDA post would mark Hahn&39;s first foray into public service in a quarter
Leer más »
FDA issues Halloween warning: Decorative contact lenses can cause blindness, infection, cornea scratches'Wouldn't it be cool to have vampire eyes for Halloween? Or deep violet eyes to match your purple sweater? How about your favorite sports team's logo on your eyes just for fun?' the FDA warning begins.
Leer más »
FDA panel recommends withdrawing approval of Makena drug, used to prevent preterm birthsA committee for the US Food and Drug Administration now recommends that the approval of Makena, a drug used to reduce the risk of preterm births, should be withdrawn — and some women who have used the medication are sounding the alarm
Leer más »
Trump to pick Texas cancer doctor to head FDA
Leer más »